Lancet Diabetes Endocrinol
-
Publication Venue For
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial..
7:618-628.
2019
-
2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial.
2019
-
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial..
6:934-943.
2018
-
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis..
6:105-113.
2018
-
Corrections needed to 2016 ESC and AHA guidelines on heart failure..
5:325-326.
2017
-
Heart failure event definitions in drug trials in patients with type 2 diabetes..
4:294-296.
2016
-
mHealth: only as good as the company it keeps..
4:7-8.
2016
-
Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants..
3:624-637.
2015
-
Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer..
3:545-555.
2015
-
Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study..
2:701-709.
2014
-
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study..
2:289-297.
2014